← Search another drug
PatientPulse · by PatientPartner
Lisinopril lisinopril
High confidence
Approximately 57 public patient-discussion pages analyzed, spanning review sites (Drugs.com, WebMD), patient forums (Mayo Clinic Connect, HealthUnlocked, Inspire), and health blogs; Drugs.com alone contributed 640+ reviews and WebMD over 4,400 ratings for lisinopril.
Executive intelligence
The signal that moves starts & adherence
28%Positive sentiment in discussion
298,722FDA adverse-event reports
60%Flagged serious
52%Reports name female patients
The persistent dry cough is the single biggest adherence killer for lisinopril, and patients who switch to ARBs rarely come back, making early cough identification the highest-value intervention window.
- The ACE inhibitor cough affects a self-reported majority of vocal online patients and is the primary driver of unsupported self-discontinuation, representing the clearest gap between label awareness and patient preparation.
- Generic manufacturer variability is a rising patient concern, with multiple reviewers attributing BP loss of control directly to pharmacy-level supplier switches rather than disease progression.
- Patients on lisinopril for CKD or diabetes report the highest ambivalence: they understand the renal-protective rationale but experience side effects at rates that erode confidence in long-term adherence.
- Lisinopril's extreme affordability (under $10 per month at GoodRx) is the single strongest loyalty driver, but it also enables patients to self-manage without physician engagement, increasing unsupervised discontinuation risk.